Telix Pharmaceuticals Ltd. has announced that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun (99mTc-besilesomab, also known as TLX66-CDx), a diagnostic radiopharmaceutical used for infection imaging. The agreement also includes a strategic contract manufacturing agreement appointing Curium as the manufacturer of the product for Telix.

Scintimun is an internationally approved product and has previously been manufactured and distributed by Curium Pharma through an out-license from Telix via the acquisition of TheraPharm in 2020.

Following a strategic review of the asset, Telix has elected to bring sales and marketing in-house, with plans to significantly augment commercial distribution and indication expansion. The company also intends to further develop Scintimun as a companion patient selection and safety assessment tool for TLX66 (90Y-besilesomab), its therapeutic bone marrow conditioning candidate for hematopoietic stem cell transplantation (HSCT).

Commenting on the development, Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, “We are pleased to be bringing Scintimun back to Telix, and see it as a valuable addition to our portfolio. In the near-term, the plan is to increase sales for its current indication by improving product availability, pricing and commercial consistency. There is significant potential to expand clinical utility, including as a ‘companion imaging’ tool for Telix's TLX66 bone marrow conditioning candidate. We look forward to leveraging its potential for expanded clinical indications in serious diseases that represent an unmet medical need.”

Ciril Faia, Chief Executive Officer, Curium Pharma Europe, added, “This agreement is a milestone for our Saclay site, as it recognises our capabilities and expertise as a contract manufacturing organization in the field of nuclear medicine. It underscores the trust placed in our teams and the quality of their work. We are pleased that Scintimun will continue to benefit thousands of patients worldwide, and we are proud to support Telix in maximising the potential of this impactful diagnostic tool.”